Professor Michele Vendruscolo, co-Director of the Centre for Misfolding Diseases.

Life in the Incubator

Our Chemistry of Health Incubator was created to nurture spin-out companies from inception through early growth. Its lab space, meeting rooms and access to department researchers provide the basis for fundamental research to be harnessed to develop new treatments for patients. It currently houses biopharmaceutical start-up Wren Therapeutics, which is focused on drug discovery and combating protein misfolding diseases, and which won £18m in a Series A financing round (2019). The daily proximity of researchers and industrial partners in the Incubator has created a synergistic process that promises to translate fundamental research into life-saving therapies, and there is further capacity to encourage research arising within this sector.